Adial Pharmaceuticals Inc ADIL

Healthcare Biotechnology

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

NDAQ:ADIL - Post by User

Adial Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 28, 2024 2:45pm

69 Views

Post# 35904579

S&P 500 Edges Lower; ADT Posts Upbeat Earnings | Benzinga

News; $ADIL S&P 500 Edges Lower; ADT Posts Upbeat Earnings | BenzingaU.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.The Dow traded down 0.27% to 3...ADIL - S&P 500 Edges Lower; ADT Posts Upbeat Earnings | Benzinga

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features